Abilify Maintena

Abilify Maintena®

(aripiprazole)

06 Dec, 2021

VIDEO HIGHLIGHTS: Exploring the Prevention of Relapse in Schizophrenia (PRELAPSE) study

Professor Malcolm Hopwood is joined by Professor John Kane, Principal Investigator and lead author, to discuss the fundamentals of the PRELAPSE study.¹The PRELAPSE study aimed to determine whether encouraging the use of Abilify Maintena® (aripiprazole) compared with clinician’s choice of treatment delayed the time to first hospitalisation in patients with early-phase illness.¹

Box

Body

Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
This product is not listed on the PBS for the treatment of bipolar 1 disorder.
text

Body

Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

Abilify Maintena PI

Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.